Role of Senescence in the Development of Endometrial Cancer

NCT ID: NCT03338985

Last Updated: 2018-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-16

Study Completion Date

2020-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q. Several genes of interest have been identified (P53, PTEN, PIK3CA, ß-catenin, K-ras ...).

A study has already been carried out at the Reims University Hospital with inclusion of patients with endometrial cancer and patients with endometrial hyperplasia. It identified specific alterations of nosologic continuum of pathology and characterize areas of interest on the genome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

make a pangenomic investigation of genetic abnormalities in atypical endometrial hyperplasia and endometrial cancers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Hyperplasia and Endometrial Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group "cases patients"

patients with endometrial hyperplasia or endometrial cancers

Group Type EXPERIMENTAL

Genetic analysis

Intervention Type GENETIC

Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic analysis

Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient with endometrial hyperplasia or endometrial cancer
* patient consenting to participate to the study
* patient enrolled in the national healthcare insurance program
* patient older than 18 years

Exclusion Criteria

\- patient with neoadjuvant chemotherapy or radiotherapy prior to surgery
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CHU de Reims

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Damien JOLLY

Reims, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emilie RAIMOND

Role: CONTACT

0326789598

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Emilie RAIMOND

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PA17002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Estrogen, Diet, Genetics and Endometrial Cancer
NCT00587886 ACTIVE_NOT_RECRUITING